首页>投融资
Silo Pharma
定向增发
Silo Pharma, Inc.于2010年7月13日在纽约州注册成立。2013年1月24日,公司将其注册地从纽约州变更为特拉华州。该公司是一家处于开发阶段的生物制药公司,专注于将传统疗法与迷幻研究相结合,以治疗患有阿尔茨海默氏症、创伤后应激障碍和其他罕见神经系统疾病等适应症的人。
基本信息
-
公司全称Silo Pharma Inc
-
类型神经系统疾病治疗用新药研发商
-
产业领域药品研发/制造、研发制造服务、生物药
-
公司人数15人以下
-
地址560 Sylvan Avenue Suite 3160 Englewood Cliffs NJ 07632
-
联系电话1-718-4009031
-
邮箱eric@silopharma.com
-
成立时间2010-01-01
投融资
-
2024-06-06定向增发200万美元未透露
-
2022-09-27上市500万美元未透露
相关投融资企业
增发
NurExone Biologic, formerly known as EnerSpar (which merged with NurExone Biologic Ltd), is a biopharmaceutical company focused on developing biologically-guided exosome therapy for patients with traumatic spinal cord injuries.In June 2022, the company completed a reverse merger with NurExone Biologic Ltd. The common shares in the capital of the Company were consolidated with each 10 pre-consolidation common shares being exchanged for 1 post-consolidation common share. As a condition of closing, the company completed a plan of arrangement on May 31, 2022, pursuant to which the company spun out its wholly-owned subsidiary 1222150 BC Ltd, including the former mining assets of the company
IPO后其他轮次
Sk Bioscience Co Ltd is a spun-out and a fully owned subsidiary of SK Inc, is a biopharmaceutical company with the main focus on vaccines.In November 2022, SK Bioscience Co Ltd donated 3 billion won to International Vaccine Institute to advance global vaccine research and development
定向增发
Silo Pharma, Inc.于2010年7月13日在纽约州注册成立。2013年1月24日,公司将其注册地从纽约州变更为特拉华州。该公司是一家处于开发阶段的生物制药公司,专注于将传统疗法与迷幻研究相结合,以治疗患有阿尔茨海默氏症、创伤后应激障碍和其他罕见神经系统疾病等适应症的人。